Racial disparities in health insurance, triple‑negative breast cancer diagnosis, tumor stage, treatment and survival in a large nationwide SEER cohort in the United States

Du,Xianglin

doi:10.3892/mco.2022.2528

Racial disparities in health insurance, triple‑negative breast cancer diagnosis, tumor stage, treatment and survival in a large nationwide SEER cohort in the United States

Authors:
- Xianglin Du
View Affiliations

Affiliations: Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX 77030 USA
Published online on: March 2, 2022 https://doi.org/10.3892/mco.2022.2528
Article Number: 95
Copyright: © Du . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It remains unclear whether there are racial disparities in mortality between women of different races who have the same subtype of breast cancer when tumor stage and size and treatment are controlled for. The present study aimed to investigate whether racial disparities in mortality existed between women of different races who had the same subtype of breast cancer when health insurance, tumor stage and size and treatment were controlled for in a large cohort of women with breast cancer in the United States. This study identified 399,564 women who were diagnosed with incident breast cancer at age ≥20 years between 2010 and 2016 in 17 Surveillance, Epidemiology and End Results (SEER) registries, including 277,319 non‑Hispanic white (white), 44,149 non‑Hispanic black (black), 34,141 non‑Hispanic Asian or Pacific Islander (Asian) and 43,955 Hispanic women. White and Asian women exhibited a lower proportion of triple‑negative breast cancer (9.8 and 9.1% respectively) than black (20.8%) and Hispanic women (12.6%). Black women had a significantly higher risk of all‑cause mortality compared with white women in only those with triple‑negative breast cancer (hazard ratio: 1.39, 95% CI: 1.29‑1.51) and those with hormone receptor‑negative/human epidermal growth factor receptor 2 (HER2)‑positive breast cancer (1.53, 1.48‑1.58) after adjusting for confounders. In those with hormone receptor‑positive breast cancer, regardless of HER2 receptor status, the risk of all‑cause mortality was not statistically different between black and white women, while the risk of breast cancer‑specific mortality was significantly higher in all subtypes of breast cancer among black women. There were racial disparities in the presentation of triple‑negative breast cancer and in all‑cause and breast cancer specific mortality following stratification by triple‑negative status and adjusting for tumor stage, size, grade and treatment.

View Figures

View References

1	Eley JW, Hill HA, Chen VW, Austin DF, Wesley MN, Muss HB, Greenberg RS, Coates RJ, Correa P, Redmond CK, et al: Racial differences in survival from breast cancer: Results of the National cancer institute black/white cancer survival study. JAMA. 272:947–954. 1994.PubMed/NCBI View Article : Google Scholar
2	Neale AV: Racial and marital status influences on 10 year survival from breast cancer. J Clin Epidemiol. 47:475–483. 1994.PubMed/NCBI View Article : Google Scholar
3	Simon MS and Severson RK: Racial differences in survival of female breast cancer in the Detroit metropolitan area. Cancer. 77:308–314. 1996.PubMed/NCBI View Article : Google Scholar
4	Howard DL, Penchansky R and Brown MB: Disaggregating the effects of race on breast cancer survival. Fam Med. 30:228–235. 1998.PubMed/NCBI
5	Yood MU, Johnson CC, Blount A, Abrams J, Wolman E, McCarthy BD, Raju U, Nathanson DS, Worsham M and Wolman SR: Race and differences in breast cancer survival in a managed care population. J Natl Cancer Inst. 91:1487–1491. 1999.PubMed/NCBI View Article : Google Scholar
6	Bradley CJ, Given CW and Roberts C: Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 94:490–496. 2002.PubMed/NCBI View Article : Google Scholar
7	Mandelblatt JS, Kerner JF, Hadley J, Hwang YT, Eggert L, Johnson LE and Gold K: OPTIONS (Outcomes and Preferences for Treatment in Older Women Nationwide Study). Variations in breast carcinoma treatment in older Medicare beneficiaries: Is it black or white? Cancer. 95:1401–1414. 2002.PubMed/NCBI View Article : Google Scholar
8	Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez C, Ghafoor A and Thun M: Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 54:78–93. 2004.PubMed/NCBI View Article : Google Scholar
9	Daly B and Olopade OI: A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin. 65:221–238. 2015.PubMed/NCBI View Article : Google Scholar
10	Iqbal J, Ginsburg O, Rochon PA, Sun P and Narod SA: Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 313:165–173. 2015.PubMed/NCBI View Article : Google Scholar
11	Daly B and Olopade OI: Race, ethnicity, and the diagnosis of breast cancer. JAMA. 313:141–142. 2015.PubMed/NCBI View Article : Google Scholar
12	Amini A, Jones BL, Yeh N, Guntupalli SR, Kavanagh BD, Karam SD and Fisher CM: Disparities in disease presentation in the four screenable cancers according to health insurance status. Public Health. 138:50–56. 2016.PubMed/NCBI View Article : Google Scholar
13	Jemal A, Lin CC, Davidoff AJ and Han X: Changes in insurance coverage and stage at diagnosis among nonelderly patients with cancer after the affordable care act. J Clin Oncol. 35:3906–3915. 2017.PubMed/NCBI View Article : Google Scholar
14	Ko NY, Hong S, Winn RA and Calip GS: Association of Insurance status and racial disparities with the detection of early-stage breast cancer. JAMA Oncol. 6:385–392. 2020.PubMed/NCBI View Article : Google Scholar
15	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.PubMed/NCBI View Article : Google Scholar
16	Cunningham JE, Montero AJ, Garrett-Mayer E, Berkel HJ and Ely B: Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control. 21:399–409. 2010.PubMed/NCBI View Article : Google Scholar
17	Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA and Cronin KA: US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 106(dju055)2014.PubMed/NCBI View Article : Google Scholar
18	Chen L and Li CI: Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Cancer Epidemiol Biomarkers Prev. 24:1666–1672. 2015.PubMed/NCBI View Article : Google Scholar
19	Newman LA and Kaljee LM: Health disparities and triple-negative breast cancer in African American women: A review. JAMA Surg. 152:485–493. 2017.PubMed/NCBI View Article : Google Scholar
20	Siddharth S and Sharma D: Racial disparity and triple-negative breast cancer in African-American women: A multifaceted affair between obesity, biology, and socioeconomic determinants. Cancers (Basel). 10(514)2018.PubMed/NCBI View Article : Google Scholar
21	Garlapati C, Joshi S, Sahoo B, Kapoor S and Aneja R: The persisting puzzle of racial disparity in triple-negative breast cancer: Looking through a new lens. Front Biosci (Schol Ed). 11:75–88. 2019.PubMed/NCBI View Article : Google Scholar
22	Kong X, Liu Z, Cheng R, Sun L, Huang S, Fang Y and Wang J: Variation in breast cancer subtype incidence and distribution by race/ethnicity in the United States From 2010 to 2015. JAMA Netw Open. 3(e2020303)2020.PubMed/NCBI View Article : Google Scholar
23	Tao L, Gomez SL, Keegan TH, Kurian AW and Clarke CA: Breast cancer mortality in African-American and non-Hispanic white women by molecular subtype and stage at diagnosis: A population-based study. Cancer Epidemiol Biomarkers Prev. 24:1039–1045. 2015.PubMed/NCBI View Article : Google Scholar
24	Brinton LA, Figueroa JD, Awuah B, Yarney J, Wiafe S, Wood SN, Ansong D, Nyarko K, Wiafe-Addai B and Clegg-Lamptey JN: Breast cancer in Sub-Saharan Africa: Opportunities for prevention. Breast Cancer Res Treat. 144:467–478. 2014.PubMed/NCBI View Article : Google Scholar
25	Prakash O, Hossain F, Danos D, Lassak A, Scribner R and Miele L: Racial disparities in triple-negative breast cancer: A review of the role of biologic and non-biologic factors. Front Public Health. 8(576964)2020.PubMed/NCBI View Article : Google Scholar
26	Dawood S, Broglio K, Kau SW, Green MC, Giordano SH, Meric-Bernstam F, Buchholz TA, Albarracin C, Yang WT, Hennessy BT, et al: Triple receptor-negative breast cancer: The effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol. 27:220–226. 2009.PubMed/NCBI View Article : Google Scholar
27	Dean-Colomb W, Yan K, Liedtke C, Symmans WF, Holmes FA, O'Shaughnessy J, Asmar L, Hortobagyi GN, Pusztai L and Gonzalez-Angulo AM: Transcriptional profiles of triple receptor-negative breast cancer: Are Caucasian, Hispanic, and African-American women different? J Clin Oncol. 26 (Suppl)(S22014)2008.
28	Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG and Eley JW: Race and triple negative threats to breast cancer survival: A population-based study in Atlanta, GA. Breast Cancer Res Treat. 113:357–370. 2009.PubMed/NCBI View Article : Google Scholar
29	Bauer KR, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer registry. Cancer. 109:1721–1728. 2007.PubMed/NCBI View Article : Google Scholar
30	Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O'Regan R, Torres MA and Meisel JL: Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 161:279–287. 2017.PubMed/NCBI View Article : Google Scholar
31	National Cancer Institute (NCI), Surveillance Epidemiology, End Results (SEER) Program: SEER*Stat Database: Incidence - SEER Research Data, Nov 2018 Sub (1975-2016) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April. 2019, based on the November 2018 submission. NCI, Bethesda, MD, 2018.
32	Gershuni V, Li YR, Williams AD, So A, Steel L, Carrigan E and Tchou J: Breast cancer subtype distribution is different in normal weight, overweight, and obese women. Breast Cancer Res Treat. 163:375–381. 2017.PubMed/NCBI View Article : Google Scholar
33	Pierobon M and Frankenfeld CL: Obesity as a risk factor for triple-negative breast cancers: A systematic review and meta-analysis. Breast Cancer Res Treat. 137:307–314. 2013.PubMed/NCBI View Article : Google Scholar
34	Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB and Lannin DR: Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database. Medicine (Baltimore). 95(e4614)2016.PubMed/NCBI View Article : Google Scholar
35	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI View Article : Google Scholar
36	Dietze EC, Sistrunk C, Miranda-Carboni G, O'Regan R and Seewaldt VL: Triple-negative breast cancer in African-American women: Disparities versus biology. Nat Rev Cancer. 15:248–254. 2015.PubMed/NCBI View Article : Google Scholar
37	Jiralerspong S and Goodwin PJ: Obesity and breast cancer prognosis: Evidence, challenges, and opportunities. J Clin Oncol. 34:4203–4216. 2016.PubMed/NCBI View Article : Google Scholar
38	Dietze EC, Chavez TA and Seewaldt VL: Obesity and triple-negative breast cancer: Disparities, controversies, and biology. Am J Pathol. 188:280–290. 2018.PubMed/NCBI View Article : Google Scholar
39	Naik A, Monjazeb AM and Decock J: The obesity paradox in cancer, tumor immunology, and immunotherapy: Potential therapeutic implications in triple negative breast cancer. Front Immunol. 10(1940)2019.PubMed/NCBI View Article : Google Scholar
40	Rose DP, Gracheck PJ and Vona-Davis L: The interactions of obesity, inflammation and insulin resistance in breast cancer. Cancers (Basel). 7:2147–2168. 2015.PubMed/NCBI View Article : Google Scholar
41	Vona-Davis L and Rose DP: The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: A review. J Womens Health (Larchmt). 18:883–893. 2009.PubMed/NCBI View Article : Google Scholar
42	Danforth DN Jr: Disparities in breast cancer outcomes between Caucasian and African American women: A model for describing the relationship of biological and nonbiological factors. Breast Cancer Res. 15(208)2013.PubMed/NCBI View Article : Google Scholar
43	Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al: Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA. 295:2492–2502. 2006.PubMed/NCBI View Article : Google Scholar
44	Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care: Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Smedley BD, Stith AY and Nelson ΑΡ (eds). National Academy Press, Washington, DC, 2002.
45	Bustos MA, Salomon MP, Nelson N, Hsu SC, DiNome ML, Hoon DS and Marzese DM: Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer. Genom Data. 12:14–16. 2017.PubMed/NCBI View Article : Google Scholar